Phase I Safety and Pharmacokinetics Study of Chiauranib in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 20 Jun 2016
Price : $35 *
At a glance
- Drugs Chiauranib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Chipscreen Biosciences
- 16 Jun 2016 Status changed from active, no longer recruiting to completed.
- 29 Jan 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
- 28 Jul 2015 Planned End Date changed from 1 Dec 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov